Thesan Pharmaceuticals Closes $16m Series A

Thesan Pharmaceuticals has closed a $16 million Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company focuses on the development of novel approaches for the treatment of dermatological disorders.

North AmericaUSBriefs